Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rapid emergence of protease inhibitor resistance in hepatitis C virus.

Science translational medicine - 5 May 2010

Rong Libin, Dahari Harel, Ribeiro Ruy M, Perelson Alan S

Abstract excerpt

About 170 million people worldwide are infected with hepatitis C virus (HCV). The current standard therapy leads to sustained viral elimination in only approximately 50% of the treated patients. Telaprevir, an HCV protease inhibitor, has substantial antiviral activity in patients with chronic HCV infection. However, in clinical trials, drug-resistant variants emerge at frequencies of 5 to 20% of the total virus...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials as Topic
Share to Drug Design
Share to Hepatocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Inhibitory Concentration 50

Share to Interferon alpha-2

Share to Oligopeptides

Share to Polyethylene Glycols

Share to Protease Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 20445200
DOI: 10.1126/scitranslmed.3000544
PMCID: PMC3033690

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rapid emergence of protease inhibitor resistance in hepatitis C virus.PMID 20445200Read ↗

Modeling quasispecies and drug resistance in hepatitis C patients treated with a protease inhibitor.Semantic proximity Read ↗

A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants.Semantic proximity Read ↗

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.Semantic proximity Read ↗

Analysis of Naturally Occurring Resistance-Associated Variants to NS3/4A Protein Inhibitors, NS5A Protein Inhibitors, and NS5B Polymerase Inhibitors in Patients With Chronic Hepatitis C.Semantic proximity Read ↗

The role of resistance in HCV treatment.Semantic proximity Read ↗

A translational study of resistance emergence using sequential direct-acting antiviral agents for hepatitis C using ultra-deep sequencing.Semantic proximity Read ↗

Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo.Semantic proximity Read ↗

Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical TrialsSemantic proximity Read ↗

Temporal dynamics of a predominant protease inhibitor-resistance mutation in a treatment-naive, hepatitis C virus-infected individual.Semantic proximity Read ↗

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients.Semantic proximity Read ↗

Resistance mutations against HCV protease inhibitors and antiviral drug design.Semantic proximity Read ↗

Superinfection and cure of infected cells as mechanisms for hepatitis C virus adaptation and persistenceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.